



PTO/SB/30 (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

<b>REQUEST FOR CONTINUED EXAMINATION (RCE) TRANSMITTAL</b> Address to: Commissioner for Patents Box RCE Washington, DC 20231	Application Number	09/416,267-Conf. #5938
	Filing Date	October 12, 1999
	First Named Inventor	Kui Su
	Group Art Unit	1646
	Examiner Name	P. Mertz
	Attorney Docket No.	PF270P1

**This is a Request for Continued Examination (RCE) under 37 CFR 1.114 of the above-identified application.**

Request for Continued Examination (RCE) practice under 37 CFR 1.114 does not apply to any utility or plant application filed prior to June 8, 1995, or to any design application. See Instruction Sheet for RCEs (not to be submitted to the USPTO) on page 2.

1. **Submission required under 37 CFR 1.114**

a. ☐ Previously submitted

i. ☐ Consider the amendment(s)/reply under 37 CFR 1.116 previously filed on \_\_\_\_\_  
(Any unentered amendment(s) referred to above will be entered).

ii. ☐ Consider the arguments in the Appeal Brief or Reply Brief previously filed on \_\_\_\_\_

iii. ☐ Other \_\_\_\_\_

b. ☒ Enclosed

i. ☒ Response

ii. ☐ Affidavit(s)/Declaration(s)

iii. ☐ Information Disclosure Statement (IDS)

iv. ☒ Other Fee Transmittal; Exhibits A-D

2. **Miscellaneous**

a. ☐ Suspension of action on the above-identified application is requested under 37 CFR 1.103(c) for a period of \_\_\_\_\_ months. (Period of suspension shall not exceed 3 months; Fee under 37 CFR 1.17(i) required)

b. ☒ Other Return Receipt Postcard

3. **Fees** The RCE fee under 37 CFR 1.17 (e) is required by 37 CFR 1.114 when the RCE is filed.

a. ☒ The Director is hereby authorized to charge the following fees, or credit any overpayments, to Deposit Account No. 08-3425

i. ☒ RCE fee required under 37 CFR 1.17(e)

ii. ☐ Extension of time fee (37 CFR 1.136 and 1.17)

iii. ☐ Other \_\_\_\_\_

b. ☐ Check in the amount of \$ \_\_\_\_\_ enclosed

c. ☐ Payment by credit card (Form PTO-2038 enclosed)

RECEIVED

MAY 14 2003

TECH CENTER 1600/2900


#22  
JGJ  
5/21/03

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT REQUIRED			
Name (Print/Type)	Janet M. Martineau	Registration No. (Attorney/Agent)	46,903
Signature		Date	May 9, 2003

05/12/2003 SSESHE1 00000123 083425 09416267

01 FC:1801 750.00 CH





VIA HAND DELIVERY MAY 9<sup>TH</sup>, 2003

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: SU et al.

Application Serial No.: 09/416,267

Art Unit: 1646

Filed: October 12, 1999

Examiner: Mertz, P.

For: Human Cytokine Polypeptide

Attorney Docket No.: PF270P1

#23  
MQJ  
5/21/03

RESPONSE UNDER 37 C.F.R. § 1.116 TO PAPER NO. 20

Commissioner for Patents

Washington, D.C. 20231

Sir:

In response to the Final Official action mailed February 10, 2003 (Paper No. 20), please consider the following remarks. Submitted concurrently herewith is: (a) a Fee Transmittal sheet; (b) a Request for Continued Examination; and (c) Exhibits A-D.

Applicants hereby request that the following remarks be entered into the above-identified application.

Remarks

Claims 25-79 are pending in this application.

RECEIVED  
MAY 14 2003  
TECH CENTER 1600/2900